Skip to main content
SpringerLink
Log in

I.E. Diabetic Vitreopathy

  • Chapter
  • First Online:
Vitreous

Abstract

Diabetes mellitus, hereafter called diabetes, is a systemic disorder of insulin signaling, resulting in hyperglycemia. Hypertension and dyslipidemia are frequent associations. The pathological results of diabetes are microvascular complications, notably retinopathy, nephropathy, and peripheral neuropathy, and accelerated atherosclerosis, resulting in major cardiovascular complications. Overnutrition is causing an international diabetes epidemic of extraordinary proportions [1]. The purpose of this discussion is to summarize the disordered metabolic pathways in diabetes with an emphasis on ocular manifestations, placing particular emphasis on how these biochemical changes alter vitreous structure and function, contributing to retinopathy and vision loss.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366:1227–39.

    PubMed  CAS  Google Scholar 

  2. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404:787–90.

    PubMed  CAS  Google Scholar 

  3. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–20.

    PubMed  CAS  Google Scholar 

  4. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A. 2000;97:12222–6.

    PubMed  CAS  PubMed Central  Google Scholar 

  5. Monnier VM, Kohn RR, Cerami A. Accelerated age-related browning of human collagen in diabetes mellitus. Proc Natl Acad Sci U S A. 1984;81:583–7.

    PubMed  CAS  PubMed Central  Google Scholar 

  6. Stitt AW. AGEs and diabetic retinopathy. Invest Ophthalmol Vis Sci. 2010;51:4867–74.

    PubMed  Google Scholar 

  7. Goh SY, Cooper ME. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab. 2008;93:1143–52.

    PubMed  CAS  Google Scholar 

  8. Zong H, Ward M, Stitt AW. AGEs, RAGE, and diabetic retinopathy. Curr Diab Rep. 2011;11:244–52.

    PubMed  Google Scholar 

  9. Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011;30:343–58.

    PubMed  CAS  PubMed Central  Google Scholar 

  10. Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR. Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. N Engl J Med. 1986;314:403–8.

    PubMed  CAS  Google Scholar 

  11. Charonis AS, Tsilbary EC. Structural and functional changes of laminin and type IV collagen after nonenzymatic glycation. Diabetes. 1992;41 Suppl 2:49–51.

    PubMed  CAS  Google Scholar 

  12. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes. 1998;47:859–66.

    PubMed  CAS  Google Scholar 

  13. Geraldes P, Hiraoka-Yamamoto J, Matsumoto M, Clermont A, Leitges M, Marette A, et al. Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat Med. 2009;15:1298–306.

    PubMed  CAS  PubMed Central  Google Scholar 

  14. Aiello LP, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes. 1997;46:1473–80.

    PubMed  CAS  Google Scholar 

  15. Danis RP, Bingaman DP, Jirousek M, Yang Y. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531. Invest Ophthalmol Vis Sci. 1998;39:171–9.

    PubMed  CAS  Google Scholar 

  16. Nonaka A, Kiryu J, Tsujikawa A, Yamashiro K, Miyamoto K, Nishiwaki H, et al. PKC-beta inhibitor (LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci. 2000;41:2702–6.

    PubMed  CAS  Google Scholar 

  17. Yokota T, Ma RC, Park JY, Isshiki K, Sotiropoulos KB, Rauniyar RK, et al. Role of protein kinase C on the expression of platelet-derived growth factor and endothelin-1 in the retina of diabetic rats and cultured retinal capillary pericytes. Diabetes. 2003;52:838–45.

    PubMed  CAS  Google Scholar 

  18. Aiello LP, Clermont A, Arora V, Davis MD, Sheetz MJ, Bursell SE. Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest Ophthalmol Vis Sci. 2006;47:86–92.

    PubMed  Google Scholar 

  19. Group P-DS. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes. 2005;54:2188–97.

    Google Scholar 

  20. Group P-D, Aiello LP, Davis MD, Girach A, Kles KA, Milton RC, et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology. 2006;113:2221–30.

    Google Scholar 

  21. Sheetz MJ, Aiello LP, Davis MD, Danis R, Bek T, Cunha-Vaz J, et al. The effect of the oral PKC beta inhibitor ruboxistaurin on vision loss in two phase 3 studies. Invest Ophthalmol Vis Sci. 2013;54:1750–7.

    PubMed  CAS  Google Scholar 

  22. Perkins BA, Aiello LP, Krolewski AS. Diabetes complications and the renin-angiotensin system. N Engl J Med. 2009;361:83–5.

    PubMed  CAS  Google Scholar 

  23. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009;361:40–51.

    PubMed  CAS  PubMed Central  Google Scholar 

  24. Xu Z, Wei Y, Gong J, Cho H, Park JK, Sung ER, et al. NRF2 plays a protective role in diabetic retinopathy in mice. Diabetologia. 2014;57:204–13.

    PubMed  CAS  PubMed Central  Google Scholar 

  25. Wei Y, Gong J, Yoshida T, Eberhart CG, Xu Z, Kombairaju P, et al. Nrf2 has a protective role against neuronal and capillary degeneration in retinal ischemia-reperfusion injury. Free Radic Biol Med. 2011;51:216–24.

    PubMed  CAS  PubMed Central  Google Scholar 

  26. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376:124–36.

    PubMed  Google Scholar 

  27. Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 2012;12:346–54.

    PubMed  Google Scholar 

  28. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology. 2008;115:1859–68.

    PubMed  PubMed Central  Google Scholar 

  29. Wei M, Gaskill SP, Haffner SM, Stern MP. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care. 1998;21:1167–72.

    PubMed  CAS  Google Scholar 

  30. Chew EY, Ferris FL, Csaky KG, Murphy RP, Agrón E, Thompson DJS, et al. The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy. Ophthalmology. 2003;110:1683–9.

    PubMed  Google Scholar 

  31. Hirai FE, Knudtson MD, Klein BE, Klein R. Clinically significant macular edema and survival in type 1 and type 2 diabetes. Am J Ophthalmol. 2008;145:700–6.

    PubMed  PubMed Central  Google Scholar 

  32. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977–86.

    Google Scholar 

  33. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.

    PubMed  CAS  Google Scholar 

  34. White NH, Sun W, Cleary PA, Danis RP, Davis MD, Hainsworth DP, et al. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol. 2008;126:1707–15.

    PubMed  Google Scholar 

  35. Gardner TW, Abcouwer SF, Barber AJ, Jackson GR. An integrated approach to diabetic retinopathy research. Arch Ophthalmol. 2011;129:230–5.

    PubMed  PubMed Central  Google Scholar 

  36. Giese MJ, Speth RC. The ocular renin-angiotensin system: a therapeutic target for the treatment of ocular disease. Pharmacol Ther. 2014;142(1):11–32.

    PubMed  CAS  Google Scholar 

  37. Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, Kita M, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med. 2005;353:782–92.

    PubMed  CAS  Google Scholar 

  38. Gao BB, Clermont A, Rook S, Fonda SJ, Srinivasan VJ, Wojtkowski M, et al. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med. 2007;13:181–8.

    PubMed  CAS  Google Scholar 

  39. Bloodworth Jr JM. Diabetic retinopathy. Diabetes. 1962;11:1–22.

    PubMed  Google Scholar 

  40. Wolter JR. Diabetic retinopathy. Am J Ophthalmol. 1961;51:1123–41.

    PubMed  CAS  Google Scholar 

  41. Antonetti DA, Barber AJ, Bronson SK, Freeman WM, Gardner TW, Jefferson LS, et al. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes. 2006;55:2401–11.

    PubMed  CAS  Google Scholar 

  42. Greenstein VC, Holopigian K, Hood DC, Seiple W, Carr RE. The nature and extent of retinal dysfunction associated with diabetic macular edema. Invest Ophthalmol Vis Sci. 2000;41:3643–54.

    PubMed  CAS  Google Scholar 

  43. Ghirlanda G, Di Leo MA, Caputo S, Cercone S, Greco AV. From functional to microvascular abnormalities in early diabetic retinopathy. Diabetes Metab Rev. 1997;13:15–35.

    PubMed  CAS  Google Scholar 

  44. van Dijk HW, Kok PH, Garvin M, Sonka M, Devries JH, Michels RP, et al. Selective loss of inner retinal layer thickness in type 1 diabetic patients with minimal diabetic retinopathy. Invest Ophthalmol Vis Sci. 2009;50:3404–9.

    PubMed  PubMed Central  Google Scholar 

  45. van Dijk HW, Verbraak FD, Kok PH, Garvin MK, Sonka M, Lee K, et al. Decreased retinal ganglion cell layer thickness in patients with type 1 diabetes. Invest Ophthalmol Vis Sci. 2010;51:3660–5.

    PubMed  PubMed Central  Google Scholar 

  46. Fortune B, Schneck ME, Adams AJ. Multifocal electroretinogram delays reveal local retinal dysfunction in early diabetic retinopathy. Invest Ophthalmol Vis Sci. 1999;40:2638–51.

    PubMed  CAS  Google Scholar 

  47. Harrison WW, Bearse Jr MA, Ng JS, Jewell NP, Barez S, Burger D, et al. Multifocal electroretinograms predict onset of diabetic retinopathy in adult patients with diabetes. Invest Ophthalmol Vis Sci. 2011;52:772–7.

    PubMed  PubMed Central  Google Scholar 

  48. Fletcher EL, Phipps JA, Ward MM, Puthussery T, Wilkinson-Berka JL. Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy. Curr Pharm Des. 2007;13:2699–712.

    PubMed  CAS  Google Scholar 

  49. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004;18:1450–2.

    PubMed  CAS  Google Scholar 

  50. Sebag J. Diabetic vitreopathy. Ophthalmology. 1996;103:205–6.

    PubMed  CAS  Google Scholar 

  51. Lundquist O, Osterlin S. Glucose concentration in the vitreous of nondiabetic and diabetic human eyes. Graefes Arch Clin Exp Ophthalmol. 1994;232:71–4.

    PubMed  CAS  Google Scholar 

  52. Xiong H, Cheng HM. Aqueous/vitreous tonicity in “sugar” cataracts. Ophthalmic Res. 1989;21:292–6.

    PubMed  CAS  Google Scholar 

  53. Cristiansson J. Changes in mucopolysaccharides during alloxan diabetes in the rabbit. I. Comparative studies on serum and the hyaluronic acid of the vitreous body. Acta Ophthalmol (Copenh). 1958;36:141–62.

    CAS  Google Scholar 

  54. Walia S, Clermont AC, Gao BB, Aiello LP, Feener EP. Vitreous proteomics and diabetic retinopathy. Semin Ophthalmol. 2010;25:289–94.

    PubMed  Google Scholar 

  55. Kim T, Kim SJ, Kim K, Kang UB, Lee C, Park KS, et al. Profiling of vitreous proteomes from proliferative diabetic retinopathy and nondiabetic patients. Proteomics. 2007;7:4203–15.

    PubMed  CAS  Google Scholar 

  56. Gao BB, Chen X, Timothy N, Aiello LP, Feener EP. Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy. J Proteome Res. 2008;7:2516–25.

    PubMed  CAS  Google Scholar 

  57. Sebag J, Buckingham B, Charles MA, Reiser K. Biochemical abnormalities in vitreous of humans with proliferative diabetic retinopathy. Arch Ophthalmol. 1992;110:1472–6.

    PubMed  CAS  Google Scholar 

  58. Buckingham B, Reiser KM. Relationship between the content of lysyl oxidase-dependent cross-links in skin collagen, nonenzymatic glycosylation, and long-term complications in type I diabetes mellitus. J Clin Invest. 1990;86:1046–54.

    PubMed  CAS  PubMed Central  Google Scholar 

  59. Sebag J, Nie S, Reiser K, Charles MA, Yu NT. Raman spectroscopy of human vitreous in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 1994;35:2976–80.

    PubMed  CAS  Google Scholar 

  60. Fankhauser 2nd F. Analysis of diabetic vitreopathy with dynamic light scattering spectroscopy–problems and solutions related to photon correlation. Acta Ophthalmol. 2012;90:e173–8.

    PubMed  Google Scholar 

  61. Sebag J. Abnormalities of human vitreous structure in diabetes. Graefes Arch Clin Exp Ophthalmol. 1993;231:257–60.

    PubMed  CAS  Google Scholar 

  62. Stitt AW, Moore JE, Sharkey JA, Murphy G, Simpson DA, Bucala R, et al. Advanced glycation end products in vitreous: structural and functional implications for diabetic vitreopathy. Invest Ophthalmol Vis Sci. 1998;39:2517–23.

    PubMed  CAS  Google Scholar 

  63. Avery NC, Bailey AJ. The effects of the Maillard reaction on the physical properties and cell interactions of collagen. Pathol Biol. 2006;54:387–95.

    PubMed  CAS  Google Scholar 

  64. Foos RY, Kreiger AE, Forsythe AB, Zakka KA. Posterior vitreous detachment in diabetic subjects. Ophthalmology. 1980;87:122–8.

    PubMed  CAS  Google Scholar 

  65. Tagawa H, McMeel JW, Furukawa H, Quiroz H, Murakami K, Takahashi M, et al. Role of the vitreous in diabetic retinopathy. I. Vitreous changes in diabetic retinopathy and in physiologic aging. Ophthalmology. 1986;93:596–601.

    PubMed  CAS  Google Scholar 

  66. Faulborn J, Dunker S, Bowald S. Diabetic vitreopathy – findings using the celloidin embedding technique. Ophthalmologica. 1998;212:369–76.

    PubMed  CAS  Google Scholar 

  67. Sebag J. Anomalous posterior vitreous detachment: a unifying concept in vitreo-retinal disease. Graefes Arch Clin Exp Ophthalmol. 2004;242:690–8.

    PubMed  CAS  Google Scholar 

  68. Akiba J, Ueno N, Chakrabarti B. Mechanisms of photo-induced vitreous liquefaction. Curr Eye Res. 1994;13:505–12.

    PubMed  CAS  Google Scholar 

  69. Ueno N, Sebag J, Hirokawa H, Chakrabarti B. Effects of visible-light irradiation on vitreous structure in the presence of a photosensitizer. Exp Eye Res. 1987;44:863–70.

    PubMed  CAS  Google Scholar 

  70. Obayashi H, Nakano K, Shigeta H, Yamaguchi M, Yoshimori K, Fukui M, et al. Formation of crossline as a fluorescent advanced glycation end product in vitro and in vivo. Biochem Biophys Res Commun. 1996;226:37–41.

    PubMed  CAS  Google Scholar 

  71. Ortwerth BJ, Prabhakaram M, Nagaraj RH, Linetsky M. The relative UV sensitizer activity of purified advanced glycation endproducts. Photochem Photobiol. 1997;65:666–72.

    PubMed  CAS  Google Scholar 

  72. Deguine V, Menasche M, Ferrari P, Fraisse L, Pouliquen Y, Robert L. Free radical depolymerization of hyaluronan by Maillard reaction products: role in liquefaction of aging vitreous. Int J Biol Macromol. 1998;22:17–22.

    PubMed  CAS  Google Scholar 

  73. Katsumura C, Sugiyama T, Nakamura K, Obayashi H, Hasegawa G, Oku H, et al. Effects of advanced glycation end products on hyaluronan photolysis: a new mechanism of diabetic vitreopathy. Ophthalmic Res. 2004;36:327–31.

    PubMed  Google Scholar 

  74. Davis MD. Vitreous contraction in proliferative diabetic retinopathy. Arch Ophthalmol. 1965;74:741–51.

    PubMed  CAS  Google Scholar 

  75. Takahashi M, Trempe CL, Maguire K, McMeel JW. Vitreoretinal relationship in diabetic retinopathy. A biomicroscopic evaluation. Arch Ophthalmol. 1981;99:241–5.

    PubMed  CAS  Google Scholar 

  76. Jalkh A, Takahashi M, Topilow HW, Trempe CL, McMeel JW. Prognostic value of vitreous findings in diabetic retinopathy. Arch Ophthalmol. 1982;100:432–4.

    PubMed  CAS  Google Scholar 

  77. Faulborn J, Bowald S. Microproliferations in proliferative diabetic retinopathy and their relationship to the vitreous: corresponding light and electron microscopic studies. Graefes Arch Clin Exp Ophthalmol. 1985;223:130–8.

    PubMed  CAS  Google Scholar 

  78. Nasrallah FP, Jalkh AE, Van Coppenolle F, Kado M, Trempe CL, McMeel JW, et al. The role of the vitreous in diabetic macular edema. Ophthalmology. 1988;95:1335–9.

    PubMed  CAS  Google Scholar 

  79. Akiba J, Arzabe CW, Trempe CL. Posterior vitreous detachment and neovascularization in diabetic retinopathy. Ophthalmology. 1990;97:889–91.

    PubMed  CAS  Google Scholar 

  80. Blankenship GW, Machemer R. Long-term diabetic vitrectomy results. Report of 10 year follow-up. Ophthalmology. 1985;92:503–6.

    PubMed  CAS  Google Scholar 

  81. Wong HC, Sehmi KS, McLeod D. Abortive neovascular outgrowths discovered during vitrectomy for diabetic vitreous haemorrhage. Graefes Arch Clin Exp Ophthalmol. 1989;227:237–40.

    PubMed  CAS  Google Scholar 

  82. Kishi S, Numaga T, Yamazaki S. Structure of the inner retinal surface in simple diabetic retinopathy. Jpn J Ophthalmol. 1982;26:141–9.

    PubMed  CAS  Google Scholar 

  83. Kishi S, Demaria C, Shimizu K. Vitreous cortex remnants at the fovea after spontaneous vitreous detachment. Int Ophthalmol. 1986;9:253–60.

    PubMed  CAS  Google Scholar 

  84. Sebag J. Vitreoschisis. Graefes Arch Clin Exp Ophthalmol. 2008;246:329–32.

    PubMed  CAS  PubMed Central  Google Scholar 

  85. Sebag J, Gupta P, Rosen RR, Garcia P, Sadun AA. Macular holes and macular pucker: the role of vitreoschisis as imaged by optical coherence tomography/scanning laser ophthalmoscopy. Trans Am Ophthalmol Soc. 2007;105:121–9; discussion 9–31.

    PubMed  PubMed Central  Google Scholar 

  86. Gupta P, Yee KM, Garcia P, Rosen RB, Parikh J, Hageman GS, et al. Vitreoschisis in macular diseases. Br J Ophthalmol. 2011;95:376–80.

    PubMed  Google Scholar 

  87. Chu TG, Lopez PF, Cano MR, Freeman WR, Lean JS, Liggett PE, et al. Posterior vitreoschisis. Ophthalmology. 1996;103:315–22.

    PubMed  CAS  Google Scholar 

  88. Schwartz SD, Alexander R, Hiscott P, Gregor ZJ. Recognition of vitreoschisis in proliferative diabetic retinopathy. Ophthalmology. 1996;103:323–8.

    Google Scholar 

  89. Gandorfer A, Rohleder M, Grosselfinger S, Haritoglou C, Ulbig M, Kampik A. Epiretinal pathology of diffuse diabetic macular edema associated with vitreomacular traction. Am J Ophthalmol. 2005;139:638–52.

    PubMed  Google Scholar 

  90. Kishi S, Shimizu K. Posterior precortical vitreous pocket. Arch Ophthalmol. 1990;108:979–82.

    PubMed  CAS  Google Scholar 

  91. Bahadir M, Ertan A, Mertoglu O. Visual acuity comparison of vitrectomy with and without internal limiting membrane removal in the treatment of diabetic macular edema. Int Ophthalmol. 2005;26:3–8.

    PubMed  Google Scholar 

  92. Barile GR, Pachydaki SI, Tari SR, Lee SE, Donmoyer CM, Ma W, et al. The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci. 2005;46:2916–24.

    PubMed  Google Scholar 

  93. Pachydaki SI, Tari SR, Lee SE, Ma W, Tseng JJ, Sosunov AA, et al. Upregulation of RAGE and its ligands in proliferative retinal disease. Exp Eye Res. 2006;82:807–15.

    PubMed  CAS  Google Scholar 

  94. Barile GR, Chang SS, Park LS, Reppucci VS, Schiff WM, Schmidt AM. Soluble cellular adhesion molecules in proliferative vitreoretinopathy and proliferative diabetic retinopathy. Curr Eye Res. 1999;19:219–27.

    PubMed  CAS  Google Scholar 

  95. Matsunaga N, Ozeki H, Hirabayashi Y, Shimada S, Ogura Y. Histopathologic evaluation of the internal limiting membrane surgically excised from eyes with diabetic maculopathy. Retina. 2005;25:311–6.

    PubMed  Google Scholar 

  96. Yamamoto T, Akabane N, Takeuchi S. Vitrectomy for diabetic macular edema: the role of posterior vitreous detachment and epimacular membrane. Am J Ophthalmol. 2001;132:369–77.

    PubMed  CAS  Google Scholar 

  97. Sun YM, Su Y, Li J, Wang LF. Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy. Biochem Biophys Res Commun. 2013;433:359–61.

    PubMed  CAS  Google Scholar 

  98. Tasman W. Diabetic vitreous hemorrhage and its relationship to hypoglycemia. Mod Probl Ophthalmol. 1979;20:413–4.

    PubMed  CAS  Google Scholar 

  99. Ikeda T, Sato K, Katano T, Hayashi Y. Vitrectomy for cystoid macular oedema with attached posterior hyaloid membrane in patients with diabetes. Br J Ophthalmol. 1999;83:12–4.

    PubMed  CAS  PubMed Central  Google Scholar 

  100. Ikeda T, Sato K, Katano T, Hayashi Y. Attached posterior hyaloid membrane and the pathogenesis of honeycombed cystoid macular edema in patients with diabetes. Am J Ophthalmol. 1999;127:478–9.

    PubMed  CAS  Google Scholar 

  101. Sebag J, Ansari RR, Dunker S, Suh KI. Dynamic light scattering of diabetic vitreopathy. Diabetes Technol Ther. 1999;1:169–76.

    PubMed  CAS  Google Scholar 

  102. Shui YB, Fu JJ, Garcia C, Dattilo LK, Rajagopal R, McMillan S, et al. Oxygen distribution in the rabbit eye and oxygen consumption by the lens. Invest Ophthalmol Vis Sci. 2006;47:1571–80.

    PubMed  Google Scholar 

  103. Siegfried CJ, Shui YB, Holekamp NM, Bai F, Beebe DC. Oxygen distribution in the human eye: relevance to the etiology of open-angle glaucoma after vitrectomy. Invest Ophthalmol Vis Sci. 2010;51:5731–8.

    PubMed  PubMed Central  Google Scholar 

  104. Stefansson E, Loftsson T. The Stokes-Einstein equation and the physiological effects of vitreous surgery. Acta Ophthalmol Scand. 2006;84:718–9.

    PubMed  Google Scholar 

  105. Barton KA, Shui YB, Petrash JM, Beebe DC. Comment on: the Stokes-Einstein equation and the physiological effects of vitreous surgery. Acta Ophthalmol Scand. 2007;85:339–40.

    PubMed  PubMed Central  Google Scholar 

  106. Gisladottir S, Loftsson T, Stefansson E. Diffusion characteristics of vitreous humour and saline solution follow the Stokes Einstein equation. Graefes Arch Clin Exp Ophthalmol. 2009;247:1677–84.

    PubMed  Google Scholar 

  107. Stefansson E. Physiology of vitreous surgery. Graefes Arch Clin Exp Ophthalmol. 2009;247:147–63.

    PubMed  Google Scholar 

  108. Yamazaki Y, Morita T. Molecular and functional diversity of vascular endothelial growth factors. Mol Divers. 2006;10:515–27.

    PubMed  CAS  Google Scholar 

  109. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480–7.

    PubMed  CAS  Google Scholar 

  110. Funatsu H, Yamashita H, Noma H, Mimura T, Yamashita T, Hori S. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol. 2002;133:70–7.

    PubMed  CAS  Google Scholar 

  111. Abu El-Asrar AM, Nawaz MI, Kangave D, Siddiquei MM, Ola MS, Opdenakker G. Angiogenesis regulatory factors in the vitreous from patients with proliferative diabetic retinopathy. Acta Diabetol. 2013;50:545–51.

    PubMed  CAS  Google Scholar 

  112. Ponsioen TL, Hooymans JM, Los LI. Remodelling of the human vitreous and vitreoretinal interface – a dynamic process. Prog Retin Eye Res. 2010;29:580–95.

    PubMed  Google Scholar 

  113. Engelen L, Stehouwer CD, Schalkwijk CG. Current therapeutic interventions in the glycation pathway: evidence from clinical studies. Diabetes Obes Metab. 2013;15:677–89.

    PubMed  CAS  Google Scholar 

  114. Gardiner TA, Anderson HR, Stitt AW. Inhibition of advanced glycation end-products protects against retinal capillary basement membrane expansion during long-term diabetes. J Pathol. 2003;201:328–33.

    PubMed  CAS  Google Scholar 

  115. Kern TS, Engerman RL. Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. Diabetes. 2001;50:1636–42.

    PubMed  CAS  Google Scholar 

  116. Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci U S A. 1991;88:11555–8.

    PubMed  CAS  PubMed Central  Google Scholar 

  117. Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, Cartwright K, et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol. 2004;24:32–40.

    PubMed  CAS  Google Scholar 

  118. Vasan S, Zhang X, Zhang X, Kapurniotu A, Bernhagen J, Teichberg S, et al. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature. 1996;382:275–8.

    PubMed  CAS  Google Scholar 

  119. Asif M, Egan J, Vasan S, Jyothirmayi GN, Masurekar MR, Lopez S, et al. An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc Natl Acad Sci U S A. 2000;97:2809–13.

    PubMed  CAS  PubMed Central  Google Scholar 

  120. Vaitkevicius PV, Lane M, Spurgeon H, Ingram DK, Roth GS, Egan JJ, et al. A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc Natl Acad Sci U S A. 2001;98:1171–5.

    PubMed  CAS  PubMed Central  Google Scholar 

  121. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med. 2003;9:294–9.

    PubMed  CAS  Google Scholar 

  122. Stitt A, Gardiner TA, Alderson NL, Canning P, Frizzell N, Duffy N, et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes. 2002;51:2826–32.

    PubMed  CAS  Google Scholar 

  123. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA. 2007;298:902–16.

    PubMed  CAS  Google Scholar 

  124. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. The Diabetic Retinopathy Vitrectomy Study Research Group. Arch Ophthalmol. 1985;103:1644–52.

    Google Scholar 

  125. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trial – Diabetic Retinopathy Vitrectomy Study Report 3. The Diabetic Retinopathy Vitrectomy Study Research Group. Ophthalmology. 1988;95:1307–20.

    Google Scholar 

  126. Hikichi T, Fujio N, Akiba J, Azuma Y, Takahashi M, Yoshida A. Association between the short-term natural history of diabetic macular edema and the vitreomacular relationship in type II diabetes mellitus. Ophthalmology. 1997;104:473–8.

    PubMed  CAS  Google Scholar 

  127. Lewis H, Abrams GW, Blumenkranz MS, Campo RV. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology. 1992;99:753–9.

    PubMed  CAS  Google Scholar 

  128. Harbour JW, Smiddy WE, Flynn Jr HW, Rubsamen PE. Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane. Am J Ophthalmol. 1996;121:405–13.

    PubMed  CAS  Google Scholar 

  129. Pendergast SD, Hassan TS, Williams GA, Cox MS, Margherio RR, Ferrone PJ, et al. Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. Am J Ophthalmol. 2000;130:178–86.

    PubMed  CAS  Google Scholar 

  130. Tachi N, Ogino N. Vitrectomy for diffuse macular edema in cases of diabetic retinopathy. Am J Ophthalmol. 1996;122:258–60.

    PubMed  CAS  Google Scholar 

  131. La Heij EC, Hendrikse F, Kessels AG, Derhaag PJ. Vitrectomy results in diabetic macular oedema without evident vitreomacular traction. Graefes Arch Clin Exp Ophthalmol. 2001;239:264–70.

    PubMed  Google Scholar 

  132. Otani T, Kishi S. A controlled study of vitrectomy for diabetic macular edema. Am J Ophthalmol. 2002;134:214–9.

    PubMed  Google Scholar 

  133. Thomas D, Bunce C, Moorman C, Laidlaw DA. A randomised controlled feasibility trial of vitrectomy versus laser for diabetic macular oedema. Br J Ophthalmol. 2005;89:81–6.

    PubMed  CAS  PubMed Central  Google Scholar 

  134. Kralinger MT, Pedri M, Kralinger F, Troger J, Kieselbach GF. Long-term outcome after vitrectomy for diabetic macular edema. Ophthalmologica. 2006;220:147–52.

    PubMed  Google Scholar 

  135. Gandorfer A, Messmer EM, Ulbig MW, Kampik A. Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane. Retina. 2000;20:126–33.

    PubMed  CAS  Google Scholar 

  136. Dillinger P, Mester U. Vitrectomy with removal of the internal limiting membrane in chronic diabetic macular oedema. Graefes Arch Clin Exp Ophthalmol. 2004;242:630–7.

    PubMed  Google Scholar 

  137. Sonoda KH, Sakamoto T, Enaida H, Miyazaki M, Noda Y, Nakamura T, et al. Residual vitreous cortex after surgical posterior vitreous separation visualized by intravitreous triamcinolone acetonide. Ophthalmology. 2004;111:226–30.

    PubMed  Google Scholar 

  138. Yanyali A, Horozoglu F, Celik E, Ercalik Y, Nohutcu AF. Pars plana vitrectomy and removal of the internal limiting membrane in diabetic macular edema unresponsive to grid laser photocoagulation. Eur J Ophthalmol. 2006;16:573–81.

    PubMed  CAS  Google Scholar 

  139. Yanyali A, Nohutcu AF, Horozoglu F, Celik E. Modified grid laser photocoagulation versus pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Am J Ophthalmol. 2005;139:795–801.

    PubMed  Google Scholar 

  140. Stolba U, Binder S, Gruber D, Krebs I, Aggermann T, Neumaier B. Vitrectomy for persistent diffuse diabetic macular edema. Am J Ophthalmol. 2005;140:295–301.

    PubMed  Google Scholar 

  141. Hartley KL, Smiddy WE, Flynn Jr HW, Murray TG. Pars plana vitrectomy with internal limiting membrane peeling for diabetic macular edema. Retina. 2008;28:410–9.

    PubMed  Google Scholar 

  142. Figueroa MS, Contreras I, Noval S. Surgical and anatomical outcomes of pars plana vitrectomy for diffuse nontractional diabetic macular edema. Retina. 2008;28:420–6.

    PubMed  Google Scholar 

  143. Yanyali A, Horozoglu F, Celik E, Nohutcu AF. Long-term outcomes of pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Retina. 2007;27:557–66.

    PubMed  Google Scholar 

  144. Kumagai K, Furukawa M, Ogino N, Larson E, Iwaki M, Tachi N. Long-term follow-up of vitrectomy for diffuse nontractional diabetic macular edema. Retina. 2009;29:464–72.

    PubMed  Google Scholar 

  145. Flaxel CJ, Edwards AR, Aiello LP, Arrigg PG, Beck RW, Bressler NM, et al. Factors associated with visual acuity outcomes after vitrectomy for diabetic macular edema: diabetic retinopathy clinical research network. Retina. 2010;30:1488–95.

    PubMed  Google Scholar 

  146. Diabetic Retinopathy Clinical Research Network Writing C, Haller JA, Qin H, Apte RS, Beck RR, Bressler NM, et al. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology. 2010;117:1087–93.e3.

    Google Scholar 

  147. Stalmans P, Benz MS, Gandorfer A, Kampik A, Girach A, Pakola S, et al. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med. 2012;367:606–15.

    PubMed  CAS  Google Scholar 

  148. Benz MS, Packo KH, Gonzalez V, Pakola S, Bezner D, Haller JA, et al. A placebo-controlled trial of microplasmin intravitreous injection to facilitate posterior vitreous detachment before vitrectomy. Ophthalmology. 2010;117:791–7.

    PubMed  Google Scholar 

  149. Diaz-Llopis M, Udaondo P, Arevalo F, Salom D, Garcia-Delpech S, Quijada A, et al. Intravitreal plasmin without associated vitrectomy as a treatment for refractory diabetic macular edema. J Ocul Pharmacol Ther. 2009;25:379–84.

    PubMed  CAS  Google Scholar 

  150. Diaz-Llopis M, Udaondo P, Millan JM, Arevalo JF. Enzymatic vitrectomy for diabetic retinopathy and diabetic macular edema. World J Diabetes. 2013;4:319–23.

    PubMed  PubMed Central  Google Scholar 

  151. de Smet MD, Castilla M. Ocriplasmin for diabetic retinopathy. Expert Opin Biol Ther. 2013;13:1741–7.

    PubMed  Google Scholar 

Download references

Acknowledgements

The authors are indebted to Matin Khoshnevis of the University of California, Irvine for preparing the section on Asteroid Hyalosis, and Christianne Wa of the Doheny Eye Institute for her assistance with literature research for this chapter.

Author information

Authors and Affiliations

  1. VMR Institute for Vitreous Macula Retina, 7677 Center Avenue, Suite 400, Huntington Beach, CA, 92647, USA

    Jesse Gale MB, ChB, MD & J. Sebag MD, FACS, FRCOphth, FARVO

  2. Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

    Jesse Gale MB, ChB, MD

  3. The Beetham Eye Institute, Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA

    Lloyd Paul Aiello MD, PhD, FARVO

Authors
  1. Jesse Gale MB, ChB, MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lloyd Paul Aiello MD, PhD, FARVO
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Sebag MD, FACS, FRCOphth, FARVO
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Sebag MD, FACS, FRCOphth, FARVO .

Editor information

Editors and Affiliations

  1. VMR Institute for Vitreous Macula Retina, Huntington Beach, California, USA

    J. Sebag

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Gale, J., Aiello, L.P., Sebag, J. (2014). I.E. Diabetic Vitreopathy. In: Sebag, J. (eds) Vitreous. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1086-1_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1086-1_5

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-1085-4

  • Online ISBN: 978-1-4939-1086-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation